NVO Jun 2024 70.000 call
| Previous close | 63.50 |
| Open | 63.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 70.00 |
| Expiry date | 2024-06-21 |
| Day's range | 63.50 - 63.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 167 |
Investor's Business DailyIs Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?
Eli Lilly stock broke out after the company reported positive results for Crohn's disease drug. Is LLY stock a buy right now?
BloombergGoldman Sachs Says Buy European Pharma Stocks Touting Innovation
(Bloomberg) -- European drugmakers that are focused on building portfolios of new medicines have gotten a nod from analysts at Goldman Sachs Group Inc.Most Read from BloombergWorld’s Largest Nuclear Plant Sits Idle While Energy Needs SoarWarning Signals Are Flashing for Homeowners in Texas and Florida‘Not Gonna Be Pretty:’ Covid-Era Homebuyers Face Huge Rate JumpInsurers Sink as UnitedHealth Sees ‘Disturbance’ in MedicaidChina Weighs Record Fine for PwC Over Evergrande Audit WorkThe analysts ini
- Yahoo Finance Video
Nvidia, advances in cancer research, climate change under Trump: Market Domination
Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.
